NCT02827851Unknown2 期
Evaluation of Safety and Effectiveness of Intraarticular Administration of Autologous Stromal Vascular Fraction of Cells for Treatment of Knee Articular Cartilage Dystrophy
Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation8 个研究点 分布在 2 个国家目标入组 200 人开始时间: 2016年5月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 200
- 试验地点
- 8
- 主要终点
- SAEs monitoring
研究概览
简要总结
Stromal vascular fraction of cells (SVF) will be extracted from lipoaspirate by enzymatic digestion. SVF will be administered in a single dose intraarticularly 4 weeks after arthroscopic debridement. All patients will receive cell therapy.This is a single arm study with no control.
详细描述
Patients undergone arthroscopic debridement for knee osteoarthritis will be subjected to abdominal liposuction under local anaesthesia. Harvested adipose tissue will be processed according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 5 ml of Hartmann's solution. Isolated SVF will be administered in a single dose into anterior part of knee joint cavity 28 days after arthroscopy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pain in the knee joint during more than a half day assessed by Visual Analog Pain Scale (score more than 40 mm)
- •At least three of the following 6 criteria: 50 years of age or older, stiffness lasting less than 30 minutes, crepitus, bony tenderness, bony enlargement, no warmth to the touch
- •Patient is able to walk without assistance
- •Patient is familiar with Participant information sheet
- •Patient signed informed consent form
- •Non-inclusion Criteria:
- •Medical history of endoprosthetic knee replacement
- •Medical history of lower extremity osteotomy
- •Medical history of knee surgery (including arthroscopy) during preceding 1 year prior to enrollment
- •Medical history of intraarticular injections during preceding 6 months prior to enrollment
- •Secondary osteoarthritis of the knee joint: posttraumatic osteoarthritis (developed after clinically significant injury), intra-articular fractures, clinically significant varus or valgus deformities of lower limbs, septic arthritis, joint's inflammatory disorders, gout, advanced chondrocalcinosis, Paget's disease, ochronosis, acromegaly, hemochromatosis, Wilson's disease, primary synovial osteochondromatosis, osteonecrosis, hemophilia
- •Patients prescribed for immunosuppressive treatment
- •Medical history of systemic autoimmune and inflammatory diseases
- •Significant weight loss (> 10% of body weight in the previous year) of unknown etiology
- •Medical history of venous thromboembolism or estimated high risk of venous thromboembolism
- •Patients prescribed for systemic corticosteroids or other medications treatment with proven impact on bone or cartilage tissue metabolism
- •Clinically significant abnormalities in results of laboratory tests
- •Any conditions limiting compliance (dementia, neuropsychiatric disease, drug and alcohol abuse etc.)
- •Participation in other clinical trials (or administration of investigational drugs) during 3 months prior inclusion
- •Patients with malignant tumors including postoperative period, patients receiving chemotherapy and/or radiotherapy.
- •Patient's activated partial thromboplastin time exceeds normal levels more than 1,8 times
- •Patients prescribed for anticoagulants treatment or patient received anticoagulants at least one hour prior liposuction
- •Medical history of heterotopic ossifications
- •Patients prescribed for glycoprotein inhibitors treatment
排除标准
- •Patient's refusal from the further participation in trial
- •Patient's refusal from compliance with the requirements of contraception during the participation in research
- •Chronic kidney disease IV- V stages (creatinine clearance < 30 mL/min estimated by Cockcroft-Gault formula)
- •Confirmed syphilis, HIV, hepatitis B or C infections
- •Dropout Criteria:
- •Pregnancy
结局指标
主要结局
SAEs monitoring
时间窗: 4 weeks after treatment
Types, probability and severity of treatment emergent serious adverse events (SAEs)
SARs monitoring
时间窗: 4 weeks after treatment
Types, probability and severity of treatment emergent serious adverse reactions (SARs)
次要结局
- Quality of life monitoring-1(Follow up to completion (up to 24 weeks after treatment))
- Quality of life monitoring-2(Follow up to completion (up to 24 weeks after treatment))
- Knee pain intensity monitoring(Follow up to completion (up to 24 weeks after treatment))
- Changes in knee joint structure-1(Follow up to completion (up to 24 weeks after treatment))
- Changes in knee joint structure-2(Follow up to completion (up to 24 weeks after treatment))
- Changes in knee function(Follow up to completion (up to 24 weeks after treatment))
- Changes in knee joint structure-3(Follow up to completion (up to 24 weeks after treatment))
研究者
研究点 (8)
Loading locations...
相似试验
Unknown
2 期
The Evaluation of Safety and Effectiveness of Intraarticular Administration of Autologous Stromal-Vascular Fraction of Adipose Tissue Cells for Treatment of Knee Joint ArthrosisKnee OsteoarthritisNCT04050111Swiss Medica XXI Century S.A.30
已完成
不适用
Safety Analysis of Implantation of Stromal Vascular FractionSafety IssuesNCT03226093Bioheart, Inc.676
暂停
不适用
Use of Stromal Vascular Fraction in Multiple SclerosisAutoimmuneMultiple SclerosisNCT03461419Healeon Medical Inc100
撤回
1 期
Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic ConditionsAutoimmuneMultiple SclerosisNCT02939859Healeon Medical Inc
Unknown
不适用
Evaluate the Use of Liposuction and Cell Separation Devices for Autologous Fat (Adipose) Derived Cells to Treat the Symptoms of Erectile DysfunctionErectile DysfunctionNCT01601353Tissue Genesis30